Generex Biotechnology: Nice Wild Speculation
by Jon C. Ogg
24/7 Wall St.
Generex Biotechnology (GNBT) describes itself as "the leader in drug delivery for metabolic diseases through the inner lining of the mouth". Not a leader, the leader. Today, a small investment bank outfit called Rodman and Renshaw opened coverage on the company with a "market outperform" rating.
The investment house said: "Our analysis indicates that Generex's oral insulin, Oral-lyn, could be a significant player in the non-injectable insulin market. We believe that Oral-lyn's product profile, combined with strong clinical data and expected rapid growth in the global diabetic population, could result in > $600 MM in revenues by 2013."
That's right,"could result" in 2013.
Continue article at 247WallSt.com
BioHealth Investor.com
______________________
24/7 Wall St.
Generex Biotechnology (GNBT) describes itself as "the leader in drug delivery for metabolic diseases through the inner lining of the mouth". Not a leader, the leader. Today, a small investment bank outfit called Rodman and Renshaw opened coverage on the company with a "market outperform" rating.
The investment house said: "Our analysis indicates that Generex's oral insulin, Oral-lyn, could be a significant player in the non-injectable insulin market. We believe that Oral-lyn's product profile, combined with strong clinical data and expected rapid growth in the global diabetic population, could result in > $600 MM in revenues by 2013."
That's right,"could result" in 2013.
Continue article at 247WallSt.com
BioHealth Investor.com
______________________
posted by Nico at
6:50 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home